Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn whether or not the combination of gemcitabine,
bevacizumab and erlotinib works in treating patients with advanced or metastatic pancreatic
cancer. Bevacizumab is a new anti-cancer drug. It is an antibody that works to slow or stop
cell growth in cancerous tumors by decreasing the blood supply to the tumors. It is approved
by the FDA for the treatment of colorectal cancer but is still considered investigational for
treating pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Genentech, Inc.